Results 91 to 100 of about 848 (155)

Clinical Mycology Today: Emerging challenges and opportunities [PDF]

open access: yes
The Mycoses Study Group Education and Research Consortium is a collective of clinicians, researchers, and educators with the common goal to advance awareness, diagnosis, and management of invasive fungal diseases.
Little, Jessica   +7 more
core   +2 more sources

Investigation of a Lomentospora prolificans case cluster with whole genome sequencing [PDF]

open access: yes, 2020
Lomentospora prolificans has caused outbreaks in immunocompromised patients. We performed whole genome sequencing (WGS) on 4 L. prolificans isolates from infections occurring during an 8-month period in the haematology unit at Hospital 1., and 2 isolates
Boan, P.   +5 more
core  

Epidemiologia, biologia, resistência a antifúngicos e virulência do fungo emergente Candida auris: Epidemiology, biology, antifungal resistance and virulence of the emerging fungus Candida auris [PDF]

open access: yes, 2022
Introdução: A Candida auris é uma nova espécie de patógeno fúngico altamente resistente e emergente que causa infecções invasivas graves. O objetivo desse estudo é realizar um levantamento sobre o gênero Candida, destacando características gerais ...
de Barros, Neuza Biguinati   +2 more
core   +1 more source

Candida Auris Features and its Treatment: Global Emergency [PDF]

open access: yes
Fungal pathogen Candida auris was identified in 2009, in Japan. Currently, it is identified in 5 continents, in more than 40 countries. Therefore, it is nowadays defined as critical priority pathogen.
Durán, Nelson   +2 more
core   +2 more sources

Molecular architecture of chitin and chitosan-dominated cell walls in zygomycetous fungal pathogens by solid-state NMR [PDF]

open access: yes
Zygomycetous fungal infections pose an emerging medical threat among individuals with compromised immunity and metabolic abnormalities. Our pathophysiological understanding of these infections, particularly the role of fungal cell walls in growth and ...
Ankur, Ankur   +6 more
core   +2 more sources

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

open access: yesAntimicrobial Agents and Chemotherapy
ABSTRACT Immunocompromised patients are susceptible to fungal infections, and drug-drug interactions with antifungals may occur due to concomitant medications. Fosmanogepix [FMGX; active moiety manogepix (MGX)] targets glycosylphosphatidylinositol-anchored mannoprotein synthesis and maturation ...
Michael R. Hodges   +5 more
openaire   +2 more sources

New preparations in systemic fungal infections [PDF]

open access: yes
Introducere Infecțiile fungice sistemice (invazive) reprezintă o problemă medicală și de sănătate publică majoră în ultimele două decenii. S-a estimat că, la nivel global, 1-1,2 miliarde de persoane sunt afectate de fungi, cu aproximativ 1,5 milioane ...
Bacinschi, Nicolae   +2 more
core  

Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. [PDF]

open access: yes
Ibrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase.
Alkhazraji, Sondus   +8 more
core   +1 more source

Drug Resist Updat [PDF]

open access: yes
Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new

core  

Home - About - Disclaimer - Privacy